Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition
Dina Stroopinsky(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Keisuke Ito(Albert Einstein College of Medicine), Turner Kufe(Beth Israel Deaconess Medical Center), Hasan Rajabi(Harvard University), Ilene Galinsky(Dana-Farber Cancer Institute), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Li Yin(Hebei Medical University), Heidi Mills(Beth Israel Deaconess Medical Center), Pier Paolo Pandolfi(University of Turin), James D. Levine(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k